Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2

BACKGROUND: Several companion diagnostic (CDx) tests for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have been approved. In our institute, the CDx test for EGFR‐TKIs was changed from the Therascreen test (Therascreen) to the Cobas EGFR v2 test (Cobas) because only Cobas w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Uchibori, Ken, Takano, Natsuki, Manabe, Ryo, Tsugitomi, Ryosuke, Ogusu, Shinsuke, Tozuka, Takehiro, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Ariyasu, Ryo, Kitazono, Satoru, Yanagitani, Noriko, Nishio, Makoto
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952781/
https://ncbi.nlm.nih.gov/pubmed/33528892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13797
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados